3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
10
Esophageal Neoplasms
4
Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Oesophago-gastric Cancer
1
KRAS and NRAS Wild-type Colorectal Cancer
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Cone Dystrophy 3
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Breast Neoplasms
1
Advanced Colorectal Cancer
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Cisplatin
8
Radiotherapy
7
Fluorouracil
6
Neoadjuvant Therapy
4
Irinotecan
4
pembrolizumab
3
Paclitaxel
3
Gefitinib
3
Carboplatin
3
toripalimab
2
spartalizumab
2
Oxaliplatin
2
Nivolumab
2
Esophagectomy
2
Docetaxel
2
vandetanib
1
tislelizumab
1
sitravatinib
1
ribociclib
1
oblimersen
1
nazartinib
1
liposomal doxorubicin
1
apatinib
1
Surgical Procedures, Operative
1
SGN-LIV1A
1
Proton Therapy
1
Pemetrexed
1
Panitumumab
1
Nutritional Support
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Esophageal Squamous Cell Carcinoma
×
Panitumumab
×
Clear all
NCT01627379
2018-03-02
POWER
AIO-Studien-gGmbH
Phase 3
Terminated
300 enrolled